Gossamer Bio, Inc..
GOSS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company's lead product candidate is Seralutinib, an inhaled formulation of a selective ...Show More
Better Health for All
-10
Gossamer Bio's entire business is devoted to developing therapeutics for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), which are serious conditions with high unmet medical needs.
1
Their lead product candidate, seralutinib, demonstrated a statistically significant, placebo-adjusted improvement of 14.3% in pulmonary vascular resistance in its Phase 2 TORREY study.
2
The company is currently conducting a global Phase 3 PROSERA study for PAH, which completed enrollment in June 2025,
3
and plans to initiate a Phase 3 trial for PH-ILD in mid-2025.
4
The company includes a 'Forward-Looking Statements' section in its press releases, cautioning about risks and uncertainties, and refers readers to its SEC filings, including the 'Risk Factors' section in its Form 10-K.
5
Gossamer Bio reported an accumulated deficit of $1,204.7 million as of June 30, 2024,
6
and $1,268.6 million as of December 31, 2024,
7
indicating substantial investment in R&D. Clinical trials are conducted under the supervision of qualified investigators in accordance with GCP regulations, requiring informed consent and Institutional Review Board (IRB) approval at each institution.
8
The Phase 3 PROSERA Study is a double-blind, placebo-controlled trial with patients assigned 1:1 to seralutinib or placebo.
9
Fair Money & Economic Opportunity
0
Gossamer Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics.
1
Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its operations. The company does not offer consumer credit products or financial services.
2
Fair Pay & Worker Respect
0
No evidence available to assess Gossamer Bio, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Gossamer Bio, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, quantitative data relevant to the 'Honest & Fair Business' ethical value was found across the provided articles. The articles primarily consist of announcements regarding board appointments and general corporate governance overviews, without detailing regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board conflict percentages, anti-corruption policies, or third-party verification of ethical claims.
1
While independent directors are mentioned, no percentage of the board free from material conflicts of interest is provided.
2
Kind to Animals
-50
Gossamer Bio, Inc. uses animals in pre-clinical studies, indicating that less than 1% of its products are certified cruelty-free.
1
The company conducts animal testing, and while there is no specific policy detailed, the use of animal testing suggests that legal mandates for such testing override the use of alternatives.
2
No War, No Weapons
0
No evidence available to assess Gossamer Bio, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles explicitly state that sustainability data is currently unavailable for Gossamer Bio, Inc.
1
No specific, concrete data points are present for any of the Planet-Friendly Business KPIs, including emissions, renewable energy use, water usage, waste diversion, green building certifications, climate targets, or environmental compliance.
2
Therefore, no KPIs can be scored based on the given evidence.
Respect for Cultures & Communities
0
No evidence available to assess Gossamer Bio, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Gossamer Bio demonstrates good user data control, with its privacy statement indicating GDPR compliance and user rights to access, correct, restrict, and delete data.
1
The company shows strong vulnerability management, achieving a mean time to resolve (MTTR) for security incident tickets of 1.8 days, a significant reduction from 21 days.
2
Furthermore, Gossamer Bio maintains good regulatory compliance, adhering to GDPR, Sarbanes-Oxley (SOX), and healthcare-related regulations, which has led to improved cyber insurance coverage and reduced costs.
3
However, the company only performs security testing on 25-40% of its systems.
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding Gossamer Bio, Inc.'s performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
The articles primarily focus on financial performance, general biopharmaceutical industry news, and drug development.
2